Jason Dinges Jason Dinges, Ph.D. Jason R. Dinges has been a member of the Morningside investment team since 2011. He has extensive experience providing operational and management oversight to early-stage biotechnology companies. Dr. Dinges is also a director of several biopharmaceutical or biotechnology companies, across a broad spectrum of therapeutic areas including: Kezar Life Sciences (NASDAQ: KZR), Enyo Pharma, CellCentric, Inotrem, ApicBio, Prilenia Therapeutics, Pinteon Therapeutics, and Allysta Pharmaceuticals. He has also facilitated multiple financings for private companies. From 2006 to 2011, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology, and Pharmaceutical practice group. Dr. Dinges received his Ph.D. in genetics from Iowa State University and a J.D., with highest distinction, from the University of Iowa College of Law.